A few GLP-1 agonists currently in phase 3 trials are higher-dose injectable semaglutide 7.2 mg (Novo Nordisk), oral semaglutide 50 mg (Novo Nordisk) and orforglipron (Eli Lilly)
This effect was associated with changes in the level of Cyclin D2, a target gene of -catenin (115)
Raz R, Weisskopf MG, Davidovitch M, Pinto O, Levine H
The human results are mixed, with small open-label studies encouraging but the controlled phase 2 OVERTURE trial missing its primary endpoint, and the larger pivotal trial has finished enrolling with results pending, so for now it is best read as mechanistically promising and clinically unproven
Direct NAD is mainly used in clinical or research settings, while NMN and NR are widely available as supplements
Lemon Bottle uses bromelain, lecithin, and riboflavin